-
Biallelic Deletion of 1p32 Defines Ultra-High-Risk Myeloma, but Monoallelic del(1p32) Remains a Strong Prognostic Factor CME / ABIM MOC
In the era of risk-adapted treatment strategies, it is crucial to detect del(1p32) at multiple myeloma diagnosis, suggests a cytogenetic study.
March 16, 2023
-
Associations of Clonal Hematopoiesis With Recurrent Vascular Events and Death in Patients With Incident Ischemic Stroke CME / ABIM MOC
Identifying genetic/other CH risk factors may improve personalized risk stratification and secondary prevention in ischemic stroke.
February 16, 2023
-
Long-Term Risk of Relapse in Immune-Mediated Thrombotic Thrombocytopenic Purpura and the Role of Anti-CD20 Therapy CME / ABIM MOC
Lack of early iTTP relapse or treatment failure predictors mandates regular ADAMTS13 monitoring to prevent progression to clinical relapse.
January 24, 2023
-
Outcomes of Patients With Aggressive B-Cell Lymphoma After Failure of Anti-CD19 CAR T-Cell Therapy: A DESCAR-T Analysis CME / ABIM MOC
Patients with R/R aggressive BCL-failing anti-CD-19 CAR T-cell therapy have an unmet medical need meriting further innovative strategy.
December 15, 2022
-
The Role of Allogeneic Transplant for Adult Ph+ ALL in CR1 With Complete Molecular Remission: A Retrospective Analysis CME / ABIM MOC
Adults with Ph+ ALL who achieved CMR within 3 months of starting treatment had lower incidence of disease relapse with allo-HCT in CR1.
November 17, 2022
-
Incidence and Impact of Anticoagulation-Associated Abnormal Menstrual Bleeding in Women After Venous Thromboembolism CME / ABIM MOC
How prevalent is abnormal uterine bleeding in women with a new venous thromboembolism diagnosis? A new study provides data to help inform clinical decisions.
October 20, 2022
-
Role of Allogeneic Transplantation in Chronic Myelomonocytic Leukemia: An International Collaborative Analysis CME / ABIM MOC
In CMML, allogeneic transplantation before transformation cuts life expectancy in lower-risk patients but may be OK for higher-risk patients.
September 22, 2022
-
Outcomes Following Treatment for ADA-Deficient Severe Combined Immunodeficiency: A Report From the PIDTC CME / ABIM MOC
In patients with ADA-SCID without infection treated after 2000, hematopoietic cell transplant vs gene therapy showed no survival difference.
August 18, 2022
-
Mechanosensation by Endothelial PIEZO1 Is Required for Leukocyte Diapedesis CME / ABIM MOC
Mice with endothelium-specific Piezo1 deficiency had decreased leukocyte extravasation in different models of inflammation, suggesting a novel target that could help regulate pathologic inflammation underlying multiple diseases.
July 21, 2022
-
Impact of Diagnostic Genetics on Remission MRD and Transplantation Outcomes in Older Patients With AML CME / ABIM MOC
In older patients with AML, molecular associations with MRD positivity and transplant outcomes are driven primarily by baseline genetics.
June 16, 2022
-
Genomic Landscape of TCRαβ and TCRγδ T-Large Granular Lymphocyte Leukemia CME / ABIM MOC
In LGL leukemia, STAT3 mutations are linked to mutational burden and neutropenia; select STAT3-activating mutations are linked to anemia.
May 19, 2022
-
Inherited Human Apollo Deficiency Causes Severe Bone Marrow Failure and Developmental Defects CME / ABIM MOC
Biallelic Apollo variants cause bone marrow failure clinically similar to DC/HH but with normal telomere length; Apollo is a genome caretaker needed for proper human immuno-hematologic system development.
April 21, 2022
-
Geriatric Assessment Predicts Nonfatal Toxicities and Survival for Intensively Treated Older Adults With AML
Among older adults with AML, geriatric assessment improved risk stratification for treatment decisions and may inform interventions to improve outcomes.
March 17, 2022
-
An Improved Index for Diagnosis and Mortality Prediction in Malignancy-Associated Hemophagocytic Lymphohistiocytosis
In HLH, the ‘optimized HLH inflammatory’ index IDed patients with hematologic malignancies and inflammatory state linked to high mortality.
February 17, 2022
-
All-Trans Retinoic Acid Plus Low-Dose Rituximab vs Low-Dose Rituximab in Corticosteroid-Resistant or Relapsed ITP
ATRA plus LD-RTX had a significant response compared with LD-RTX monotherapy and may be helpful to treat resistant or relapsed adult ITP.
January 20, 2022
-
HLA Associations, Somatic Loss of HLA Expression, and Clinical Outcomes in Immune Aplastic Anemia
In immune aplastic anemia, HLA-B*14 and HLA class I allele loss are linked to high-risk clonal evolution after IST; more studies are needed.
December 30, 2021
-
IgM-MM Is Predominantly a Pre-Germinal Center Disorder and Has a Distinct Genomic and Transcriptomic Signature From WM
Molecular and transcriptomic characterization of IgM-multiple myeloma identifies its origin at an early stage of plasma cell differentiation and suggests potential therapeutic targets.
November 18, 2021
-
Tumor Cells in Light-Chain Amyloidosis and Myeloma Show Distinct Transcriptional Rewiring of Normal Plasma Cell Development
Survival in light-chain amyloidosis and multiple myeloma is inferior when tumor cells express transcriptional programs of more immature normal plasma cell stages.
October 28, 2021
-
Relationship Between Clone Metrics and Clinical Outcome in Clonal Cytopenia
In patients with clonal cytopenia, clone metrics allow estimation of disease progression risk and may inform clinical decision making.
September 16, 2021
-
Genetic Identification of Patients With AML Older Than 60 Years Achieving Long-term Survival With Intensive Chemotherapy
A simple genetic model can predict overall survival in older patients with AML treated with standard intensive 7+3 chemotherapy, which may help guide clinical trials and treatment decisions.
August 19, 2021
